Avid Bioservices Inc (CDMO)

[InternetForumUser]

Galaxy-2 Trial Size ~500 @ 140 Centers:

Apr. 22, 2013-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that the first patients have been treated in the randomized GALAXY-2 Phase 3 trial designed to evaluate docetaxel plus ganetespib, its investigational Hsp90 inhibitor, versus docetaxel alone for the second-line treatment of non-small cell lung adenocarcinoma. The study will enroll approximately 500 patients from about 140 cancer treatment centers worldwide.